Results from a Phase III clinical trial have Bayer AG saying their drug can extend the lives of liver cancer patients, according to Reuters.
The drug the company is speaking of is called Regorafenib.
And according to Reuters, the company's next move is to file for regulatory approval of the oncology compound.